Transforming growth factor beta peptide antagonists and their conversion to partial agonists

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Transforming growth factor beta (TGF-beta) plays a role in human disease pathogenesis.
• Developing synthetic TGF-beta antagonists offers potential therapeutic strategies.

Purpose of the Study:

• To develop and characterize novel synthetic pentapeptides as TGF-beta antagonists.
• To investigate the structure-activity relationship of these antagonists.

Main Methods:

• Synthesis of three pentacosapeptides (beta125-(41-65), beta225-(41-65), beta325-(41-65)) corresponding to TGF-beta isoforms.
• Assay of TGF-beta isoform binding inhibition to receptors in mink lung epithelial cells.
• Evaluation of TGF-beta1-induced growth inhibition and PAI-1 expression.
• Site-directed mutagenesis to create alanine substitution variants.
• Assessment of conjugated peptide activity.

Main Results:

• Synthetic pentacosapeptides inhibited TGF-beta isoform binding to receptors with IC50 values of 0.06-2 microM.
• beta125-(41-65) effectively blocked TGF-beta1-induced growth inhibition and PAI-1 expression.
• Mutant peptides (W52A/D55A and R52A/D55A) lacked TGF-beta antagonist activity.
• Conjugation of beta125-(41-65) enhanced antagonist activity but also induced partial agonist activity.

Conclusions:

• The (W/R)XXD motif is crucial for the TGF-beta antagonist activity of these synthetic peptides.
• This motif may represent the active site sequence of TGF-beta.
• These findings support the therapeutic potential of synthetic TGF-beta antagonists.